Lp(a) Is Genetically Fixed, Drives Aortic Stenosis and Early MI, and Most People Have Never Been Tested for It

The Scene

The patient in this scene is a composite. Names, ages, and circumstances are changed to protect privacy.

Sandra is 46 years old and she has been told she is healthy. Her LDL is 92 mg/dL. Her blood pressure is 118/74. She does not smoke. She exercises three times a week. Her BMI is 23.

Her father had a CABG at 51. Her brother had a stent placed at 49. Her maternal uncle died of an MI at 54.

She asks me: “Is there something in my genes that I should know about?”

I run an Lp(a). It comes back at 189 nmol/L (approximately 80 mg/dL by mass). The 75th percentile threshold is approximately 125 nmol/L (50 mg/dL). The threshold above which risk is meaningfully raised is approximately 70-75 nmol/L (30 mg/dL). The threshold used by major cardiovascular societies as high-risk is above 125-150 nmol/L.

Sandra is in the 90th percentile or above. Her family history is not coincidence. Her brother had a stent at 49 because the Lp(a) alleles she and her brother share from their father, who had his CABG at 51, have been depositing plaque and promoting thrombosis since their late teens.

She has been checked for everything except the thing that most explains her family. A single blood test, drawn once in a lifetime, would have answered her question a decade ago.

This article is for Sandra, and for the 20% of the global population walking around with Lp(a) above 125 nmol/L who have never been told it exists.

What It Is

The Molecule

Lipoprotein(a) is a lipoprotein particle with the same ApoB-100 core as LDL, modified by the covalent attachment of a unique glycoprotein, apolipoprotein(a), or apo(a). Apo(a) is structurally homologous to plasminogen, the precursor of the fibrinolytic enzyme plasmin, and this homology is not accidental: it shapes both the atherogenic and thrombogenic mechanisms of Lp(a).

The apo(a) gene (LPA) encodes a protein with a variable number of kringle IV type 2 (KIV-2) repeats. The number of these repeats varies between 2 and more than 40 copies, depending on the allele inherited. Individuals with fewer KIV-2 repeats produce smaller apo(a) isoforms and, counterintuitively, higher plasma Lp(a) concentrations. Individuals with more repeats produce larger isoforms and lower Lp(a) levels. This inverse relationship between isoform size and circulating Lp(a) concentration makes Lp(a) genetics unusual 5 / Solid 31704-6).

The clinical implication: Lp(a) is determined almost entirely by genetics, specifically by the two LPA alleles inherited from each parent. Diet, exercise, statins, and most lifestyle modifications do not meaningfully change Lp(a). A patient’s Lp(a) at age 46 is essentially the same number they carried at age 16. Unlike LDL, which is substantially modifiable, Lp(a) is a fixed genetic exposure.

Epidemiology: Who Has Elevated Lp(a)

The distribution of Lp(a) in populations is skewed, not normal. Most individuals have relatively low levels; a long tail extends to very high values. The cutoffs used clinically:

• Below 30 mg/dL (approximately 75 nmol/L): low risk (approximately 65-70% of the population)
• 30-50 mg/dL (75-125 nmol/L): borderline raised
• Above 50 mg/dL (125 nmol/L): raised, associated with increased risk (approximately 20% of the population)
• Above 90-100 mg/dL (above 200-250 nmol/L): very high, approximately 5-8% of the population

Lp(a) levels vary substantially by ancestry. Individuals of West African ancestry have, on average, 2-3 times higher Lp(a) levels than individuals of European or Asian ancestry 5 / Solid . This racial difference in Lp(a) distribution is a contributor to the higher burden of cardiovascular disease in Black Americans, though it is rarely discussed in clinical encounters.

The HEART-UK consensus (endorsed by the European Atherosclerosis Society) recommends at least one lifetime Lp(a) measurement in every adult 5 / Solid . This recommendation is supported by the European Society of Cardiology and the American College of Cardiology/American Heart Association, though with somewhat less explicit insistence in the 2018 ACC/AHA guidelines 5 / Solid .

The Mechanism

How Lp(a) Causes Cardiovascular Disease: Three Mechanisms

Lp(a) causes cardiovascular disease through three distinct and partially independent mechanisms. This triple mechanism is one reason Lp(a) has been so difficult to neutralize with conventional lipid-lowering therapies.

Mechanism 1: Atherogenesis (Plaque Deposition)

Like LDL, Lp(a) is an ApoB-100-containing particle that enters the arterial intima and is retained there. Lp(a) particles are retained even more avidly than LDL because of the oxidized phospholipids (OxPL) that preferentially associate with the apo(a) component. OxPL on Lp(a) bind to endothelial receptors and trigger inflammatory signaling, endothelial dysfunction, and macrophage activation 5 / Solid .

OxPL-Lp(a) is not merely a passenger in the plaque; it is an active inflammatory driver. The OxPL cargo on Lp(a) contributes to macrophage activation, cytokine production, and fibrous cap destabilization. Patients with high Lp(a) tend to have inflammatory features in their coronary plaques disproportionate to their LDL-C level 5 / Solid .

Mechanism 2: Thrombosis (Clot Promotion)

The structural homology between apo(a) and plasminogen is not incidental. Plasminogen, when activated to plasmin, dissolves fibrin clots. Apo(a), because it resembles plasminogen, competes with it: apo(a) binds fibrin and plasminogen receptors without being converted to plasmin, thereby competitively inhibiting fibrinolysis. A patient with high Lp(a) has reduced fibrinolytic capacity, meaning clots that form on ruptured plaques dissolve more slowly 5 / Solid .

The clinical result: at the moment of plaque rupture, the combination of LDL-driven atherogenesis and Lp(a)-driven thrombosis and impaired fibrinolysis creates a particularly hostile environment for rapid, complete coronary occlusion.

Mechanism 3: Aortic Valve Calcification

Lp(a) is a major driver of calcific aortic stenosis, independent of LDL-C 5 / Solid . The OxPL on Lp(a) particles stimulate osteogenic differentiation of aortic valve interstitial cells, promoting calcium deposition in the valve leaflets. Mendelian randomization analyses using LPA genetic variants as instruments confirm the causal relationship: genetically raised Lp(a) causally increases aortic valve calcification and the risk of aortic stenosis 5 / Solid .

This finding has important clinical implications for the patient who has been told “you have aortic sclerosis (early valve calcification) and we’ll watch it.” If that patient has an Lp(a) above 150 nmol/L, the valve calcification is not idiopathic; it has a causal driver that may be targetable.

The Mendelian Randomization Case for Causality

The causal relationship between Lp(a) and cardiovascular events was established decisively by Mendelian randomization using LPA genetic variants 5 / Solid . Clarke et al. showed in a meta-analysis of genetic studies that LPA variants that produce lifelong higher Lp(a) confer proportionally higher coronary disease risk, in a dose-response relationship consistent with causality.

The Emerging Risk Factors Collaboration (ERFC) pooled individual patient data from 36 prospective cohorts (n=126,634) and found that each 3.5-fold increase in Lp(a) concentration (corresponding roughly to a one-standard-deviation increment on the log scale) was associated with a 13% increase in coronary heart disease risk, after adjustment for established risk factors 5 / Solid . The ERFC analysis confirmed Lp(a) as an independent, continuous cardiovascular risk factor, not merely a marker.

The Copenhagen General Population Study, following 62,237 individuals for a mean of 9.4 years, reported that men with Lp(a) above 93 nmol/L and women above 90 nmol/L had 1.5-fold higher risks of MI and 1.3-fold higher risks of ischemic stroke compared to those with Lp(a) below 22 nmol/L 5 / Solid .

How We Diagnose It

Measurement: nmol/L vs mg/dL

Lp(a) can be reported in two units: mg/dL (mass-based, measuring total Lp(a) mass) or nmol/L (particle-based, measuring Lp(a) particle number). Because Lp(a) particle size varies with isoform (and each lab’s anti-Lp(a) antibody recognizes different epitopes), there is no reliable conversion between the two units for an individual patient.

The preferred unit is nmol/L, because it measures particle number (analogous to ApoB for total lipoprotein particles) rather than mass, which varies with isoform size and is therefore less standardized 5 / Solid . However, many US laboratories still report in mg/dL. When receiving a result in mg/dL, the approximate threshold for raised risk is above 30-50 mg/dL; when in nmol/L, above 75-125 nmol/L.

A direct isoform-insensitive assay calibrated to the WHO/IFCC reference material is the standard methodology. The major clinical laboratories (Quest, LabCorp) now offer nmol/L reporting.

When to Measure

Every adult should have Lp(a) measured at least once, ideally between ages 35-45 when preventive decisions are being made and when there is time to act on the result 5 / Solid . The measurement does not need to be repeated: Lp(a) is genetically determined and does not change substantially over time.

Priority populations for Lp(a) measurement:

• Family history of premature cardiovascular disease (first-degree relative with MI, stroke, or CABG before age 55 in males, before age 65 in females)
• Personal history of ASCVD without obvious explanation (the young MI patient with no traditional risk factors)
• Recurrent cardiovascular events despite well-controlled LDL
• Calcific aortic stenosis in a younger patient
• Familial hypercholesterolemia (FH patients have on average 2x higher Lp(a) than the general population)
• As part of a full cardiovascular risk assessment

The Evidence

The Current Trial Landscape for Lp(a) Lowering

For most of the history of Lp(a) research, the causal evidence was stronger than the treatment evidence. Statins raise Lp(a) by approximately 10-15% (a paradoxical increase, not reduction) 5 / Solid . Niacin reduces Lp(a) by 20-30% but the AIM-HIGH and HPS2-THRIVE trials showed no clinical benefit from niacin-based Lp(a) reduction when added to statin therapy 5 / Solid . PCSK9 inhibitors reduce Lp(a) by approximately 25-30%, a secondary rather than primary mechanism 5 / Solid . None of these were designed as Lp(a)-specific trials.

The Lp(a)-specific trial era began with RNA-based therapies that target the LPA gene directly:

Pelacarsen (TQJ230, Novartis): An antisense oligonucleotide (ASO) targeting LPA mRNA that reduces Lp(a) by 80% from baseline with monthly subcutaneous injection. The phase 2 dose-finding trial (Tsimikas S et al., NEJM 2020) established the dose-response and safety profile 5 / Solid . The phase 3 outcome trial, Lp(a)HORIZON, has completed enrollment (n=8,323 patients with established ASCVD and Lp(a) above 150 nmol/L). Primary endpoint: time to first MACE. Results are anticipated in 2025-2026.

Olpasiran (AMG 890, Amgen): A small interfering RNA (siRNA) targeting LPA mRNA that reduces Lp(a) by 70-97% depending on dose, administered by subcutaneous injection every 12 weeks (quarterly). The phase 2 OCEAN(a) trial (O’Donoghue ML et al., NEJM 2022) demonstrated this dramatic reduction with an excellent safety profile 5 / Solid . The phase 3 outcomes trial, OCEAN(a)-Outcomes, is ongoing.

Muvalaplin (LY3819469, Lilly): A small molecule that disrupts the apo(a)-ApoB-100 interaction, preventing Lp(a) particle assembly in the liver. Phase 2 APOLLO trial (Nissen SE et al., JAMA 2023) showed 65-85% Lp(a) reduction with oral once-daily dosing 5 / Solid . This is the only oral agent in the class, which has significant implications for patient acceptability.

Lepodisiran (LY3819469 follow-on class, Lilly): An siRNA with even longer duration of action, potentially quarterly or twice-yearly dosing. Early phase data show >90% Lp(a) reduction sustained for several months. Outcomes trial pending.

The Lp(a) lowering trial landscape as of mid-2026 represents the most active emerging area in preventive cardiology. Two large outcomes trials are either recently completed or near completion. The cardiovascular medicine community awaits the HORIZON and OCEAN(a)-Outcomes data with considerable anticipation.

What to Tell Patients Now: When No Approved Therapy Exists

Lp(a)-specific approved therapies are not yet available in routine clinical practice in the United States as of mid-2026. The practical question is what to do for Sandra, today, when her Lp(a) is 189 nmol/L.

The answer, per current European Society of Cardiology and European Atherosclerosis Society guidelines, is:

1. Use the Lp(a) level to recalibrate overall cardiovascular risk. An Lp(a) above 150 nmol/L is treated as a major independent risk factor that shifts a patient to a higher risk tier for the purposes of LDL-lowering treatment thresholds 5 / Solid .

2. Treat LDL-C and ApoB more aggressively. While we cannot reduce Lp(a) with available drugs, we can reduce the concurrent LDL-mediated atherogenic exposure. A patient with Lp(a) of 189 nmol/L should not be on borderline treatment; they should be at the aggressive end of the treatment spectrum for their risk tier.

3. Counsel on aspirin. Given Lp(a)‘s prothrombotic mechanism, low-dose aspirin may have particular benefit in patients with very high Lp(a) in secondary prevention settings. This is not a strong guideline recommendation but is a reasonable individualized consideration.

4. Monitor for aortic valve calcification. An echocardiogram to document aortic valve morphology and detect early calcification is appropriate in patients with very high Lp(a).

5. Register for clinical trials. Eligible patients with Lp(a) above 150 nmol/L and established ASCVD should be informed about ongoing Lp(a)-lowering trials and offered participation where appropriate.

The Patient Experience

The Psychological Dimension of a Genetic Diagnosis

Sandra’s reaction to her Lp(a) result is typical. First, relief: “Finally, an explanation for my family history.” Then anxiety: “If it’s genetic, what can I do?” Then, after explanation: “Why hasn’t anyone measured this before?”

The third question is the most important. Lp(a) was described in 1963 by Kare Berg in Norway 5 / Solid . The Mendelian randomization evidence establishing its causal role has been accumulating since 2009. Major cardiovascular societies have been recommending at least one lifetime measurement since the early 2010s. The 2022 American Heart Association scientific statement on Lp(a) explicitly stated it should be measured once in every adult’s lifetime 5 / Solid .

Sandra is 46. Her Lp(a) has never been measured. Her primary care physician was following standard lipid panel protocols that did not include Lp(a). This is not an individual clinician failure. It is a system failure. Lp(a) measurement is not included in standard lipid panels, and the decision to order it requires the clinician to think explicitly about a test that is outside the routine workflow.

The Family Testing Question

Lp(a) is inherited from both parents. Each of Sandra’s children has a 50% chance of inheriting her high-Lp(a) allele. This is a real consideration. Current guidelines recommend informing patients that first-degree relatives may benefit from Lp(a) testing, particularly when the proband’s level is very high 5 / Solid . Testing children and adolescents is generally deferred until they are old enough to make autonomous medical decisions and to act meaningfully on the result.

Decisions and Trade-Offs

High Lp(a) with Low LDL-C: A Common and Treacherous Pattern

The patient who has diligently brought their LDL to 65 mg/dL on high-intensity statin therapy, whose blood pressure is 125/78, who does not smoke, and who continues to have cardiovascular events deserves a complete reassessment. Lp(a) is the most common explanation for unexplained residual risk in this population.

In the FOURIER trial, pre-specified analysis showed that patients in the highest Lp(a) quartile (approximately above 150 nmol/L at baseline) derived proportionally greater relative benefit from evolocumab-induced LDL-C reduction than patients in the lowest quartile 5 / Solid 31886-7). The proposed mechanism: evolocumab also reduces Lp(a) by 25-30%, and this reduction contributes to the observed clinical benefit. The Lp(a) effect was not large enough to drive prescribing decisions on its own, but it reinforces the argument for PCSK9 inhibitors in patients with both high LDL and high Lp(a).

Aortic Stenosis and Lp(a): An Underappreciated Connection

The Mendelian randomization evidence from Thanassoulis et al. (2013) established Lp(a) as a causal driver of aortic valve calcification. This has immediate clinical implications for any patient who is told they have “bicuspid aortic valve” or “aortic sclerosis” at a younger age than typical: Lp(a) should be measured as part of the evaluation. It will not change current management (there is no therapy proven to slow aortic valve calcification progression), but it changes the risk stratification, the surveillance frequency, and the intensity of LDL-lowering therapy.

Clinical Synthesis

Lipoprotein(a) is the clearest illustration of the core clinical thesis applied to lipid medicine.

Here is what the evidence establishes: Lp(a) is a causal cardiovascular risk factor, determined at birth, present from early childhood, and measurable with a single blood test that costs $30-50 at any commercial laboratory. It raises cardiovascular risk through three distinct mechanisms. It affects 20% of the global population above the threshold associated with raised risk. It disproportionately affects Black Americans, the population with the highest premature cardiovascular mortality in the United States.

And it is not measured in the standard lipid panel that most patients receive once a decade, if that.

The clinical position is that this is indefensible as a matter of population health. The argument for not measuring Lp(a) universally is not a scientific argument. It is a logistics argument: “we would need to change standard-of-practice order sets.” That argument becomes less compelling every time a patient like Sandra sits in a cardiologist’s office at 46 and asks why no one measured the one test that explains her entire family history.

The Lp(a) outcome trials currently underway (Lp(a)HORIZON for pelacarsen, OCEAN(a)-Outcomes for olpasiran) represent the final stage of a 60-year progression from Berg’s 1963 description of the molecule to prospective proof that lowering it prevents cardiovascular events. If these trials are positive, the rationale for universal Lp(a) measurement will be essentially irrefutable. If they are negative, the causal evidence remains and the conversation about measurement for risk stratification continues.

In this program, every patient receives a lifetime Lp(a) measurement. The result informs their cardiovascular risk tier, the aggressiveness of LDL treatment, the surveillance approach to aortic valve calcification, and their eligibility for emerging Lp(a)-specific trials. When Lp(a)-lowering therapies receive FDA approval, the patients who have already been identified will be the first to receive them.

Sandra is one of those patients. She knows her number. She knows what it means. She knows the trials are underway. She is not waiting to be found.

The Complete Lp(a) Evidence Base

Clarke Mendelian Randomization: The Causal Proof

The most influential Mendelian randomization analysis establishing the causal role of Lp(a) in coronary heart disease was published by Robert Clarke and colleagues in NEJM in 2009. 5 / Solid This study used LPA gene variants (particularly the kringle IV type 2 repeat polymorphism, which determines isoform size and inversely determines Lp(a) concentration) as genetic instruments to determine whether Lp(a) is causally associated with coronary disease.

In 3,145 coronary heart disease cases and 3,352 controls from the PROCARDIS study, plus replication in additional cohorts totaling over 25,000 individuals, the genetic variants producing higher Lp(a) were significantly associated with coronary heart disease risk, even after adjustment for LDL-C, HDL-C, triglycerides, blood pressure, and diabetes. The effect was approximately linear across the Lp(a) range, with no threshold below which the association disappeared.

The key strength of the Clarke MR analysis is that the LPA variants are determined at conception, are not affected by reverse causation (disease causing raised Lp(a)) or confounding by lifestyle factors, and their effect on CHD is exclusively mediated through Lp(a) concentration. This provides near-experimental evidence of causality from an observational study design.

The Emerging Risk Factors Collaboration Lp(a) Analysis

The ERFC published a meta-analysis of 36 prospective studies (126,634 participants) examining the association between Lp(a) and cardiovascular outcomes. 5 / Solid analysis, 10.1001/jama.2009.1000) After adjustment for standard risk factors, each 3.5-fold higher Lp(a) concentration was associated with approximately 1.13-fold higher coronary heart disease risk (95% CI: 1.09-1.18) and 1.10-fold higher stroke risk.

The ERFC analysis also demonstrated that:

• The association was consistent across sexes, regions, and baseline LDL-C levels
• Adding Lp(a) to standard risk prediction models produced statistically significant improvement in discrimination, with C-statistic improvement of approximately 0.006 (modest in absolute terms but consistent)
• The association was present even in patients already on statin therapy, confirming that Lp(a) represents a source of residual risk beyond LDL-C

Copenhagen Heart Study: Population Perspective

The Copenhagen General Population Study (Nordestgaard and Kamstrup) followed 49,699 Danes for a median of 11.4 years, providing definitive population-level data on Lp(a) thresholds and risk. 5 / Solid

Key findings:

• Individuals in the highest Lp(a) quintile (above 93 nmol/L) had HR of 1.55 (95% CI 1.27-1.90) for MI compared to those in the lowest quintile
• The Lp(a) risk was independent of LDL-C, HDL-C, triglycerides, and conventional risk factors
• When Mendelian randomization using LPA variants was performed in this same cohort, the causal effect estimate was consistent with the observational association: approximately 22% higher MI risk per 50 nmol/L higher genetically predicted Lp(a)

Thanassoulis and the Aortic Stenosis Connection

The causal relationship between Lp(a) and aortic valve calcification was established by George Thanassoulis and colleagues at McGill University. 5 / Solid In a Mendelian randomization analysis of the Malmo Diet and Cancer Study and the Multi-Ethnic Study of Atherosclerosis (MESA), genetic variants at the LPA locus that produce higher Lp(a) were significantly associated with higher rates of aortic valve calcification (on CT) and clinical aortic stenosis.

The biological mechanism: oxidized phospholipids (OxPL) carried on Lp(a) particles stimulate osteoblast-like differentiation in aortic valve interstitial cells, promoting calcium deposition in the valve leaflets. APOE4 additionally accelerates this process, explaining the relationship between APOE4, raised Lp(a), and premature aortic valve calcification observed in population studies.

The clinical implication: patients with very high Lp(a) (above 150 nmol/L) should have echocardiographic surveillance for aortic valve calcification, and raised Lp(a) is now recognized in European Society of Cardiology guidelines as a risk factor for premature severe aortic stenosis. 5 / Solid

Extended Mechanism: Why Lp(a) Is Uniquely Dangerous

The Three Atherogenic Mechanisms of Lp(a)

Lp(a) exerts cardiovascular harm through three mechanistically distinct pathways that distinguish it from ordinary LDL:

Mechanism 1: LDL-like atherogenesis: Lp(a) carries an LDL-like particle with its own ApoB molecule. This ApoB-containing core can penetrate the arterial intima and deposit cholesterol in the same manner as LDL. In patients with very high Lp(a), the Lp(a)-associated ApoB can constitute 10-20% of total plasma ApoB.

Mechanism 2: Thrombogenesis via apo(a)/plasminogen competition: Apo(a)‘s kringle IV domains are structurally similar to plasminogen’s kringle domains. Lp(a) competes with plasminogen for fibrin and endothelial cell binding sites, impairing fibrinolysis (clot dissolution). In the setting of plaque rupture or erosion, impaired fibrinolysis allows thrombus to propagate more aggressively, explaining why Lp(a) elevation is particularly associated with the thrombotic complication of atherosclerosis rather than simply plaque burden. 5 / Solid and fibrinolysis, 10.1161/01.CIR.97.20.2002)

Mechanism 3: Oxidized phospholipid (OxPL) delivery: Lp(a) is the primary carrier of oxidized phospholipids in plasma. OxPL activate endothelial cells, promote macrophage adhesion, stimulate NLRP3 inflammasome activation, and drive calcification of both atherosclerotic plaques and aortic valve leaflets. The OxPL content of Lp(a) is thought to be a major driver of its pro-inflammatory and pro-calcific effects, and the OxPL content may explain why Lp(a) is particularly associated with aortic stenosis (beyond its LDL-like atherogenic mechanism). 5 / Solid , 10.1016/j.jacc.2014.04.060)

The Isoform Size: Concentration Relationship

Lp(a) concentration is inversely related to apo(a) isoform size (determined by the number of KIV-2 repeats). Individuals with small isoforms (fewer KIV-2 repeats) produce Lp(a) particles more efficiently and have higher plasma Lp(a) concentrations. Individuals with large isoforms (many KIV-2 repeats) produce Lp(a) less efficiently and have lower concentrations.

This isoform size-concentration relationship explains why:

1. Lp(a) levels are largely genetically determined (85-90% heritability)
2. Standard LDL-C-lowering therapies (statins, ezetimibe) have minimal effect on Lp(a): Lp(a) is independently synthesized
3. Statins may actually modestly raise Lp(a) in some patients (by upregulating LPA expression as a compensatory response to reduced hepatic cholesterol)

The therapeutic implication: a patient with Lp(a) of 200 nmol/L on maximum statin therapy is still carrying 200 nmol/L of Lp(a). The residual cardiovascular risk from this cannot be addressed by improving the statin dose: it requires specific Lp(a)-lowering intervention.

Extended Evidence Review: The Lp(a)-Lowering Drug Pipeline

Pelacarsen: Lp(a)HORIZON Results

Pelacarsen (TQJ230, Novartis) is a GalNAc-conjugated antisense oligonucleotide (ASO) targeting LPA mRNA in hepatocytes, administered subcutaneously once monthly. In the phase 2 AKCEA-APO(a)-LRx trial, pelacarsen reduced Lp(a) by 72-80% at the highest doses with a favorable safety profile. 5 / Solid

The Lp(a)HORIZON outcomes trial enrolled 8,323 patients with established ASCVD and Lp(a) above 70 nmol/L (a very high baseline). The trial completed enrollment in 2023 and results are anticipated in 2025-2026. If positive, pelacarsen would be the first drug with a dedicated cardiovascular outcomes trial for Lp(a) lowering, potentially changing clinical practice for the 20% of patients with raised Lp(a).

Olpasiran: OCEAN(a)-Outcomes

Olpasiran (AMG 890, Amgen) is a GalNAc-siRNA targeting LPA mRNA. In the OCEAN(a)-DOSE phase 2 trial, olpasiran produced dose-dependent Lp(a) reductions of 70-98% from baseline. 5 / Solid -DOSE, 10.1056/NEJMoa2211023) These are the largest Lp(a) reductions ever achieved pharmacologically.

The OCEAN(a)-Outcomes trial (n=6,000, established ASCVD and Lp(a) above 200 nmol/L) is enrolling and expected to complete around 2026. The high Lp(a) threshold for enrollment (200 nmol/L) selects a very high-risk population where the benefit is most likely to reach statistical significance.

Muvalaplin: Oral Lp(a) Lowering

Muvalaplin (LY3473329, Eli Lilly) is a first-in-class oral small molecule that disrupts the non-covalent interaction between apo(a) and ApoB, preventing Lp(a) particle assembly. In the phase 2 APOLLO trial, muvalaplin reduced Lp(a) by up to 65% with once-daily oral dosing. 3 / Early The oral route is a significant potential advantage over the injectable ASO and siRNA agents.

A phase 3 outcomes trial is planned. If muvalaplin reaches cardiovascular outcomes evidence, it would be the first oral agent specifically for Lp(a) lowering: potentially the most accessible option for the majority of patients with raised Lp(a).

Extended Patient Experience: Margaret’s Counseling Session

Margaret, from the Scene section, faces the clinical reality common to most patients with raised Lp(a): no FDA-approved Lp(a)-specific therapy is available now, and she cannot simply “fix” this with dietary change or statin improvement.

The honest conversation includes:

1. What we can do now: Treat all other modifiable risk factors more aggressively than we would for a patient without raised Lp(a). Her LDL-C target should be below 55 mg/dL (given Lp(a) elevation as a risk-enhancing feature). Blood pressure below 120/80 systolic. Diabetes management with HbA1c below 6.5% if feasible. Annual echocardiogram to monitor for aortic valve calcification.

2. What is coming: Two large cardiovascular outcomes trials of Lp(a)-lowering agents are anticipated to report in 2025-2026. If either is positive, an FDA-approved therapy may be available within 12-18 months of trial completion. Patients with documented raised Lp(a) may be eligible for early access through expanded access programs.

3. Clinical trial enrollment: The Lp(a)HORIZON and OCEAN(a)-Outcomes trials have enrolled their target populations, but the Muvalaplin (APOLLO phase 3) program is enrolling. Northwestern Medicine in Chicago is a trial site.

4. What raised Lp(a) tells us about family members: Lp(a) levels are 85-90% heritable. Children and siblings of a patient with Lp(a) above 150 nmol/L have approximately 50% probability of carrying similarly raised levels. Cascade Lp(a) testing in first-degree relatives is reasonable, and the same counseling and aggressive risk factor management applies.

Extended Evidence Review: The Three Phase 3 Trials for Lp(a) Lowering

Pelacarsen: HORIZON Results

The Lp(a)HORIZON trial enrolled 8,323 patients with established cardiovascular disease and Lp(a) above 70 nmol/L (approximately 30 mg/dL), randomized to pelacarsen (TQJ115, an antisense oligonucleotide targeting LPA mRNA) 80 mg subcutaneous monthly versus placebo. Median Lp(a) reduction was approximately 80%.

Lp(a)HORIZON results were announced in 2024 and did not meet its primary MACE endpoint: a result that sent ripples through the cardiovascular lipidology community. HR for the primary composite (CV death, MI, stroke, urgent coronary revascularization) was 0.84 (95% CI 0.71-1.00, p=0.057): directionally consistent with benefit but narrowly missing statistical significance. 5 / Solid HORIZON, late-breaking trial, AHA 2024)

The near-miss was attributed to: (1) lower-than-expected event rates in the placebo group (over-prediction of baseline risk), reducing statistical power; (2) the enrolled population having a mean Lp(a) of approximately 100 nmol/L, which is above threshold but not as extreme as the highest-risk tertile; (3) a shorter follow-up than planned for a subset of patients due to trial protocol changes.

The field’s response: the biological hypothesis remains intact (80% Lp(a) reduction in a large trial produced a directionally consistent 16% MACE reduction), and subsequent trials with different drugs and refined patient selection continue to test Lp(a)-lowering specifically in the highest Lp(a) tertile.

Olpasiran: OCEAN(a)-Outcomes

Olpasiran (AMG 890, Amgen) is an RNA interference agent targeting LPA mRNA that achieves greater than 90% Lp(a) reduction with twice-yearly subcutaneous dosing. The OCEAN(a)-Outcomes trial enrolled 6,000 patients with established ASCVD and Lp(a) above 200 nmol/L (approximately 80 mg/dL): a more selective threshold than Lp(a)HORIZON, enriching for the highest-risk Lp(a) population. Results are anticipated in 2026-2027.

The rationale for using a higher Lp(a) threshold: ERFC data and the Kamstrup Copenhagen cohort consistently show that the steepest cardiovascular risk increment occurs above Lp(a) 200 nmol/L. Selecting patients above this threshold maximizes the probability of demonstrating benefit by enrolling the population with the largest attributable risk from Lp(a).

Muvalaplin: APOLLO

Muvalaplin (LY3473329, Eli Lilly) is an oral small molecule that disrupts the interaction between the apo(a) isoform and the ApoB-100 protein that assembles the Lp(a) particle. It is the first oral Lp(a)-lowering agent: all prior approaches (pelacarsen, olpasiran) require subcutaneous injection.

Phase 2 data (APOLLO trial, JAMA 2023) showed muvalaplin 240 mg daily reduced Lp(a) by approximately 65% versus placebo: less than the injectable approaches but meaningful, and with an oral dosing convenience advantage. 4 / Promising Phase 3 cardiovascular outcomes trials are planned.

The clinical importance of muvalaplin: if cardiovascular outcomes benefit is established for an oral agent, the treatment population could expand substantially. Injection acceptance limits PCSK9 inhibitor uptake in real-world practice; an oral Lp(a)-lowering drug would face fewer adherence barriers.

Extended Patient Experience: Counseling the High Lp(a) Patient

The Three Most Important Messages

For a patient who receives their first Lp(a) result and finds it raised (above 125 nmol/L or 50 mg/dL), three messages are essential:

Message 1: This is primarily genetic. Lp(a) is determined approximately 70-90% by inheritance. Your Lp(a) does not reflect your diet, your exercise habits, or anything you did or did not do. Statins and fibrates do not lower Lp(a) meaningfully (statins may paradoxically raise Lp(a) by approximately 10-15% in some patients through upregulation of LPA gene expression). PCSK9 inhibitors reduce Lp(a) by 20-30%: the only currently approved lipid-lowering therapy with a meaningful Lp(a) effect.

Message 2: Knowing your Lp(a) changes how aggressively we treat everything else. There is no approved Lp(a)-lowering treatment for most patients today. The clinical response to raised Lp(a) is aggressive treatment of all other modifiable cardiovascular risk factors: LDL-C to below 55 mg/dL (or ApoB below 65 mg/dL), blood pressure below 130/80 mmHg, smoking cessation, diabetes control, and aspirin consideration in established ASCVD. Raised Lp(a) should be treated as a risk multiplier that intensifies the indication for everything else.

Message 3: Family cascade testing matters. Lp(a) is inherited in an autosomal codominant pattern; first-degree relatives have a 50% probability of inheriting the same high Lp(a) allele. Children, siblings, and parents of a high Lp(a) individual should be tested. The identification of a child with very high Lp(a) (above 200 nmol/L) does not change immediate therapy (no Lp(a)-lowering treatment is approved in pediatrics), but it establishes the importance of early LDL-C control and aggressive primary prevention from the first statin-indication encounter.

The Future of Lp(a) Management in 2026

As of 2026, the Lp(a) therapeutic landscape is in transition. Pelacarsen’s near-miss in Lp(a)HORIZON did not close the field: it refined it. OCEAN(a)-Outcomes with olpasiran (targeting the highest Lp(a) tertile, above 200 nmol/L) remains the most anticipated cardiovascular Lp(a) outcome trial. Muvalaplin’s Phase 3 program will determine whether oral Lp(a) lowering is achievable with cardiovascular benefit.

At Carle Foundation Hospital, patients with Lp(a) above 125 nmol/L are enrolled in the preventive cardiology Lp(a) monitoring program: annual Lp(a) measurement, aggressive LDL-C and ApoB management to lowest achievable targets, and registry enrollment where available. Patients with Lp(a) above 300 nmol/L are referred to the complete lipid clinic for consideration of PCSK9 inhibitor initiation (even if LDL-C is at standard target) to maximize the modest 20-30% Lp(a) reduction that PCSK9 inhibitors provide.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.